his best bet is

來源: jaydad 於 2013-01-13 20:27:55 [] [博客] [舊帖] [給我悄悄話] 閱讀數 : (298 bytes)
回答: 急性淋巴細胞性白血病請教 由 xinxinren 於 2013-01-13 15:24:34

ponatinib, or Iclusig, formally known as AP24534 in clinical trials, made by a Boston-based company Ariad Pharmaceuticals, Inc. 

Iclusig was approved by FDA about a month ago, for treatment of AML and Ph+ ALL that can no longer be controlled by Gleevac and chemotherapies. 

所有跟帖： 

• should also mention -jaydad- ♂ 給 jaydad 發送悄悄話 jaydad 的博客首頁 (434 bytes) () 01/13/2013 postreply 21:14:13

• Thank you so much, that is good news! but -xinxinren- ♀ 給 xinxinren 發送悄悄話 (90 bytes) () 01/14/2013 postreply 11:50:24

請您先登陸，再發跟帖！